Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Diagnosis and assessment of Takayasu arteritis by multiple biomarkers.

Ishihara T, Haraguchi G, Tezuka D, Kamiishi T, Inagaki H, Isobe M.

Circ J. 2013;77(2):477-83. Epub 2012 Oct 26.

2.

Matrix metalloproteinases as novel disease markers in Takayasu arteritis.

Matsuyama A, Sakai N, Ishigami M, Hiraoka H, Kashine S, Hirata A, Nakamura T, Yamashita S, Matsuzawa Y.

Circulation. 2003 Sep 23;108(12):1469-73. Epub 2003 Sep 2.

3.

Sensitive assessment of activity of Takayasu's arteritis by pentraxin3, a new biomarker.

Ishihara T, Haraguchi G, Kamiishi T, Tezuka D, Inagaki H, Isobe M.

J Am Coll Cardiol. 2011 Apr 19;57(16):1712-3. doi: 10.1016/j.jacc.2010.10.058. No abstract available.

4.

Pentraxin-3 as a marker of disease activity in Takayasu arteritis.

Dagna L, Salvo F, Tiraboschi M, Bozzolo EP, Franchini S, Doglioni C, Manfredi AA, Baldissera E, Sabbadini MG.

Ann Intern Med. 2011 Oct 4;155(7):425-33. doi: 10.7326/0003-4819-155-7-201110040-00005.

PMID:
21969341
5.

Systemic pentraxin-3 levels reflect vascular enhancement and progression in Takayasu arteritis.

Tombetti E, Di Chio MC, Sartorelli S, Papa M, Salerno A, Bottazzi B, Bozzolo EP, Greco M, Rovere-Querini P, Baldissera E, Del Maschio A, Mantovani A, De Cobelli F, Sabbadini MG, Manfredi AA.

Arthritis Res Ther. 2014 Nov 14;16(6):479. doi: 10.1186/s13075-014-0479-z.

6.

Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients.

Huang CY, Wu TC, Lin WT, Leu HB, Lin CP, Lin SJ, Chen JW.

Eur J Clin Invest. 2006 Feb;36(2):76-84.

PMID:
16436088
7.

Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.

Chen CH, Lin KC, Yu DT, Yang C, Huang F, Chen HA, Liang TH, Liao HT, Tsai CY, Wei JC, Chou CT.

Rheumatology (Oxford). 2006 Apr;45(4):414-20. Epub 2005 Nov 15.

PMID:
16287916
8.

MMP-9 and IL-6 are potential biomarkers for disease activity in Takayasu's arteritis.

Sun Y, Ma L, Yan F, Liu H, Ding Y, Hou J, Jiang L.

Int J Cardiol. 2012 Apr 19;156(2):236-8. doi: 10.1016/j.ijcard.2012.01.035. Epub 2012 Feb 12. No abstract available.

PMID:
22330005
9.

Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease.

Wu TC, Leu HB, Lin WT, Lin CP, Lin SJ, Chen JW.

Eur J Clin Invest. 2005 Sep;35(9):537-45.

PMID:
16128859
10.

Elevated serum levels of proinflammatory cytokines and biomarkers of matrix remodeling in never-treated patients with familial hypercholesterolemia.

El Messal M, Beaudeux JL, Drissi A, Giral P, Chater R, Bruckert E, Adlouni A, Chapman MJ.

Clin Chim Acta. 2006 Apr;366(1-2):185-9. Epub 2005 Nov 8.

PMID:
16280123
11.

Elevated plasma pentraxin 3 levels are associated with development and progression of diabetic retinopathy in Korean patients with type 2 diabetes mellitus.

Yang HS, Woo JE, Lee SJ, Park SH, Woo JM.

Invest Ophthalmol Vis Sci. 2014 Aug 26;55(9):5989-97. doi: 10.1167/iovs.14-14864.

PMID:
25159210
12.

Human pentraxin 3 (PTX3) as a novel biomarker for the diagnosis of pulmonary arterial hypertension.

Tamura Y, Ono T, Kuwana M, Inoue K, Takei M, Yamamoto T, Kawakami T, Fujita J, Kataoka M, Kimura K, Sano M, Daida H, Satoh T, Fukuda K.

PLoS One. 2012;7(9):e45834. doi: 10.1371/journal.pone.0045834. Epub 2012 Sep 21.

13.

Differences in biomarkers in patients with heart failure with a reduced vs a preserved left ventricular ejection fraction.

de Denus S, Lavoie J, Ducharme A, O'Meara E, Racine N, Sirois MG, Neagoe PE, Zhu L, Rouleau JL, White M.

Can J Cardiol. 2012 Jan-Feb;28(1):62-8. doi: 10.1016/j.cjca.2011.09.007. Epub 2011 Nov 21.

PMID:
22104539
14.

Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris.

Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, Sagara M, Miyamoto K, Satoh H, Kohno I, Kurata T, Ota H, Mantovani A, Hamakubo T, Daida H, Kodama T.

Arterioscler Thromb Vasc Biol. 2007 Jan;27(1):161-7. Epub 2006 Nov 9.

15.

Usefulness of plasma matrix metalloproteinase-9 level in predicting future coronary revascularization in patients after acute myocardial infarction.

Wang KF, Huang PH, Chiang CH, Hsu CY, Leu HB, Chen JW, Lin SJ.

Coron Artery Dis. 2013 Jan;24(1):23-8. doi: 10.1097/MCA.0b013e32835aab4a.

PMID:
23151854
16.

Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis.

Kanesaka T, Mori M, Hattori T, Oki T, Kuwabara S.

J Neurol Neurosurg Psychiatry. 2006 Feb;77(2):185-8.

17.

Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment.

Ribbens C, Martin y Porras M, Franchimont N, Kaiser MJ, Jaspar JM, Damas P, Houssiau FA, Malaise MG.

Ann Rheum Dis. 2002 Feb;61(2):161-6.

18.

Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease.

Zeng B, Prasan A, Fung KC, Solanki V, Bruce D, Freedman SB, Brieger D.

Intern Med J. 2005 Jun;35(6):331-5.

PMID:
15892761
19.

Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes.

Lee SW, Song KE, Shin DS, Ahn SM, Ha ES, Kim DJ, Nam MS, Lee KW.

Diabetes Res Clin Pract. 2005 Aug;69(2):175-9.

PMID:
16005367
20.

Serological markers in psoriatic arthritis: promising tools.

Ramonda R, Modesti V, Ortolan A, Scanu A, Bassi N, Oliviero F, Punzi L.

Exp Biol Med (Maywood). 2013 Dec;238(12):1431-6. doi: 10.1177/1535370213506435. Epub 2013 Oct 21.

PMID:
24146263

Supplemental Content

Support Center